{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:49:17Z","timestamp":1791532157710,"version":"4.3.4"},"reference-count":12,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jtct.2026.09.024","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:55:41Z","timestamp":1791528941000},"page":"1184-1186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u2018A Bridge Too CAR? Who Benefits from Bridging Therapy in 2026?\u2019 [\u201cImpact of Bridging Response on Outcomes after CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma\u201d \u2013 Wills et al. Transplant Cell Ther 2026]"],"prefix":"10.1016","volume":"32","author":[{"given":"Michael","family":"Northend","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Roddie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jtct.2026.09.024_bib0001","first-page":"1270","article-title":"Impact of Bridging Response on Outcomes after CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma","volume":"32","author":"Wills","year":"2026","journal-title":"Transplantation and Cellular Therapy"},{"issue":"12","key":"10.1016\/j.jtct.2026.09.024_bib0002","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","article-title":"Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma","volume":"7","author":"Roddie","year":"2023","journal-title":"Blood Advances"},{"issue":"24","key":"10.1016\/j.jtct.2026.09.024_bib0003","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1182\/blood.2023021620","article-title":"Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume","volume":"143","author":"Locke","year":"2024","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2026.09.024_bib0004","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s00277-021-04560-6","article-title":"Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy","volume":"100","author":"Iacoboni","year":"2021","journal-title":"Ann Hematol"},{"issue":"22","key":"10.1016\/j.jtct.2026.09.024_bib0005","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.jtct.2026.09.024_bib0006","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Advances"},{"issue":"22","key":"10.1016\/j.jtct.2026.09.024_bib0007","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.1158\/1078-0432.CCR-24-0830","article-title":"Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma","volume":"30","author":"Hubbeling","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2026.09.024_bib0008","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1182\/blood-2025-3734","article-title":"Comprehensive analysis of bridging to CAR-T cell therapy in large B-cell lymphoma with conventional treatment or the CD3xCD20 bispecific antibody glofitamab","volume":"146","author":"Fluemann","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.09.024_bib0009","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1182\/blood-2025-2770","article-title":"Preliminary data on epcoritamab and glofitamab as bridging therapy prior to CAR T-cell treatment in Relapsed\/Refractory large B cell lymphoma","volume":"146","author":"PIAZZOLA","year":"2025","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2026.09.024_bib0010","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/bjh.19453","article-title":"Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK","volume":"205","author":"Kuhnl","year":"2024","journal-title":"British Journal of Haematology"},{"issue":"13","key":"10.1016\/j.jtct.2026.09.024_bib0011","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1182\/bloodadvances.2025015855","article-title":"Bridging radiotherapy before chimeric antigen receptor T cells for B-cell lymphomas: an ILROG multicenter study","volume":"9","author":"Yegya-Raman","year":"2025","journal-title":"Blood Advances"},{"issue":"8","key":"10.1016\/j.jtct.2026.09.024_bib0012","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/bloodadvances.2023011767","article-title":"Applying the EHA\/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality","volume":"8","author":"Rejeski","year":"2024","journal-title":"Blood Adv"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726007281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726007281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:55:47Z","timestamp":1791528947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726007281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":12,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2666636726007281"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.09.024","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u2018A Bridge Too CAR? Who Benefits from Bridging Therapy in 2026?\u2019 [\u201cImpact of Bridging Response on Outcomes after CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma\u201d \u2013 Wills et al. Transplant Cell Ther 2026]","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.09.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}